US Bancorp DE Has $2.16 Million Position in Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• US Bancorp DE increased its stake in Fresenius Medical Care AG & Co. KGaA by 225.5%, owning 75,660 shares valued at $2.16 million after acquiring an additional 52,418 shares in the second quarter.
• The company reported a quarterly earnings per share (EPS) of $0.52, surpassing analyst estimates of $0.50, along with revenue of $5.54 billion for the quarter.
• Several institutional investors have recently altered their positions in Fresenius Medical Care, with a total of 8.37% of the company's stock held by institutional investors and hedge funds.

US Bancorp DE boosted its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 225.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 75,660 shares of the company's stock after purchasing an additional 52,418 shares during the quarter. US Bancorp DE's holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,162,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Pzena Investment Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 0.6% during the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company's stock valued at $382,890,000 after purchasing an additional 94,065 shares during the period. Millennium Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company's stock valued at $26,982,000 after purchasing an additional 361,364 shares during the period. Todd Asset Management LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter valued at approximately $12,009,000. Hennessy Advisors Inc. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $11,479,000. Finally, Northern Trust Corp boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company's stock valued at $9,468,000 after buying an additional 18,061 shares during the period. Institutional investors and hedge funds own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock opened at $26.62 on Thursday. The company's fifty day simple moving average is $25.50 and its 200-day simple moving average is $26.27. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The firm has a market cap of $15.62 billion, a PE ratio of 21.82, a P/E/G ratio of 0.63 and a beta of 0.92. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.94 and a 12 month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. Equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a "sell" rating to an "underperform" rating in a report on Wednesday. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Finally, Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of "Hold" and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.